Annals of Oncology Advance Access published online on March 5, 2008
Annals of Oncology, doi:10.1093/annonc/mdn051
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org
letter to the editor |
Prolonged neutropenia after dose-dense chemotherapy with pegfilgrastim
| The first 10% of the full text of this article appears below. |
In the dose-dense (DD) chemotherapy trial result reported by Piedbois et al. [1], they found more hematological toxicity leading to treatment discontinuation in the pegfilgrastim supported DD chemotherapy arm. The manufacturer's product information for pegfilgrastim indicates that it should be used once per chemotherapy cycle and should not
1 Department of Clinical Trial Management/Outpatient Oncology Unit, Translational Research Center
2 Department of Translational Clinical Oncology/Outpatient Oncology Unit
3 Department of Breast Surgery, Kyoto University Hospital, Kyoto 606-8507, Japan
4 Ithaca Medical Group, Ithaca, NY 14850, USA
* (E-mail: hishimd@kuhp.kyoto-u.ac.jp)